Skip to main content

Cell avidity measurements directly linked to synapse quality and in vivo tumor clearance

Find out how measuring cell avidity could reduce cell therapy development timelines and improve in vivo CAR-NK efficacy

Get full insights on how cell avidity can be applied to CAR-NK development

Learn from our Field Application Scientist how CAR-NK therapy emerges as a novel cell therapy for cancer, and how measuring cell avidity provides valuable information that enables researchers to select the best candidates most likely to succeed in vivo and in clinical trials.

Leading research teams reveal cell avidity of CAR-NK cells as the best and earliest predictive parameter for 𝙞𝙣 𝙫𝙞𝙫𝙤 tumor control

Tumors are often able to escape from immune surveillance using trogocytosis, a mechanism where innate cells accumulate inhibitory molecules torn from the tumor. Recent work using cell avidity measurements by the Gottschalk lab at St. Jude Children’s Research Hospital (published in Nature Biotechnology) and the Rezvani lab at MD Anderson Cancer Center (published in Nature Medicine) revealed new mechanisms to overcome trogocytosis-mediated escape and improve solid tumor clearance in vivo.

Peter Chockley

Dr. Chockley presented his work published in Nature Biotechnology “Synapse-tuned CARs enhance immune cell anti-tumor activity”.

"Most influential were the avidity measurements that directly interrogated the strength of the synapse."

Chockley et al, 2023 in Nature Biotechnology and Li et al, 2022 in Nature Medicine show that cell avidity increases in vivo anti-tumor efficiency by tuning synapse interactions.

Key takeaways:

  • Cell avidity is used to identify CAR-NK cells with improved synapse strength and in vivo tumor clearance, leading to potential improvements in therapeutic efficacy.
  • Enhanced avidity helps to overcome trogocytosis-mediated relapse and improves in vivo tumor clearance, thus prolonging the survival rate of CAR-NK cells by tuning synapse interactions.
  • High-avidity CAR-NK cells display lower levels of trogocytosis than low-avidity cells.
z-Movi Workflow for Website_1

Schematic figure of the z-Movi workflow depicting measurements of two different immune-cell populations with different avidities to the monolayer of target cells and the resulting avidity curves.

Why use the z-Movi?

Because it is the only tool that allows you to reliably select the best CAR-NK and other immune cell variants, saving you invaluable time and costs.

Find out more about the z-Movi here.

z-Movi<sup>®</sup> High-throughput Label-free Cell Interaction Studies

Speak with an expert

Want to learn more about the z-Movi Cell Avidity Analyzer? Whether you would like to speak to an expert, request a demo, or simply request more information, we would be happy to connect with you.

Request more information
Close Menu

For pricing, reach out to your application scientist or account manager

Open Email

Fill in our contact form, we will reach out to you!

Please include ‘Lakeview data analysis price inquiry’ in the Message box

Contact Us

Fill in the form and get access to the on-demand webinar

By submitting the form you agree to LUMICKS' privacy policy.

By submitting the form you agree to LUMICKS' privacy policy.

Join our newsletter

Get exclusive news on the latest publications, product developments, events and breakthrough science.

By submitting the form you agree to LUMICKS' privacy policy. You can revoke your consent at any time.

Download our webinar recording:


Download our Cell Therapy (CAR-T, TCR, NK) applications deck